Latest Antiseptic Stories
NEWARK, N.J., Nov. 23, 2010 /PRNewswire/ -- BioNeutral Group (OTC Bulletin Board: BONU), a specialty technology-based life science company, today announced it has received independent laboratory results from MicroChem Laboratory Inc. indicating that Ygiene(TM) Hospital Grade antimicrobial eliminated tuberculosis in under five minutes. Dr. Norman Miner, owner and operator of MicroChem Laboratories was retained by H. Paul Dorman CEO of DFB Pharmaceuticals, to conduct an independent Standard...
MORRIS PLAINS, N.J., May 18 /PRNewswire/ -- The makers of LISTERINE® Antiseptic introduce "This Is Your Mouth," a docummercial narrated by award-winning actor Neil Patrick Harris (CBS's How I Met Your Mother). By blending pop culture with science and a good dose of humor, this fast-paced video takes a closer look at the potential effects of rapidly multiplying bacteria in the mouth and illustrates how LISTERINE® Antiseptic destroys the millions of germs that are left behind from...
In the news release, "Ansell Launches World's First Antimicrobial Surgical Glove" issued on 4 May 2010 05:00 GMT, by Ansell Healthcare over PR Newswire, we are advised by a representative of the company that an extra "s" was accidentally added in "World's" in the headline by PR Newswire prior to distribution. Complete, corrected release follows: MELBOURNE, May 4, 2010 /PRNewswire/ -- Ansell Launches World's First Antimicrobial Surgical Glove Ansell today announced the...
MELBOURNE, May 4, 2010 /PRNewswire/ -- Ansell today announced the launch of their new GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology, at the Annual Congress of the Royal Australasian College of Surgeons in Perth, Australia. It is the first surgical glove which incorporates a proprietary antimicrobial coating to provide an additional level of protection to surgical staff against viruses and bacteria, in the event of a breach during surgery. The last decade has...
The U.S. Food and Drug Administration announced Thursday that it was reviewing the safety of triclosan, which is a popular antibacterial agent found in soap, toothpaste and a variety of other products. Although the agency said there are no grounds to recommend any changes in the use of triclosan, some say recent studies merit a closer look. Reuters reports that Massachusetts Democrat Edward Markey feels there should be strict limits. "Despite the fact that this chemical is found in...
- SDA Responds to Challenges on Effectiveness, Safety of Antibacterial Ingredient - Consumers Can Continue to Use Antibacterial Hygiene Products with Confidence WASHINGTON, April 8 /PRNewswire-USNewswire/ -- The Soap and Detergent Association today expressed concern over statements made by the Food and Drug Administration (FDA) on the effectiveness of a key ingredient used in beneficial antibacterial soaps and body washes. SDA said it will continue providing an informed perspective to the...
ASAP(R) Antibacterial Silver Wound Dressing Gel is now cleared as a 510(k) medical device "for use in the management of 1st and 2nd degree burns, stasis...pressure...(and) diabetic ulcers, lacerations, abrasions, skin tears, surgical incision sites, device insertion site wounds, graft sites and donor sites"; new ASAP product "has been shown (in laboratory tests) to inhibit the growth of...(Staph...E. coli...MRSA and VRE as well as...Candida." SALT LAKE CITY, UT, Nov. 17 /PRNewswire/ -...
PITTSBURGH, Oct. 13 /PRNewswire/ -- BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and...
EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These two separate laboratory studies of its...
EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies...
